These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25669748)

  • 1. Short-interval observational data to inform clinical trial design in Huntington's disease.
    Hobbs NZ; Farmer RE; Rees EM; Cole JH; Haider S; Malone IB; Sprengelmeyer R; Johnson H; Mueller HP; Sussmuth SD; Roos RA; Durr A; Frost C; Scahill RI; Landwehrmeyer B; Tabrizi SJ
    J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1291-8. PubMed ID: 25669748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.
    D JF; Stout JC; Poudel G; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    Br J Psychiatry; 2016 Jun; 208(6):571-8. PubMed ID: 26678864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.
    Peinemann A; Schuller S; Pohl C; Jahn T; Weindl A; Kassubek J
    J Neurol Sci; 2005 Dec; 239(1):11-9. PubMed ID: 16185716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study.
    Domínguez D JF; Egan GF; Gray MA; Poudel GR; Churchyard A; Chua P; Stout JC; Georgiou-Karistianis N
    PLoS One; 2013; 8(9):e74131. PubMed ID: 24066104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials.
    Müller HP; Huppertz HJ; Dreyhaupt J; Ludolph AC; Tabrizi SJ; Roos RAC; Durr A; Landwehrmeyer GB; Kassubek J
    Parkinsonism Relat Disord; 2019 Jun; 63():179-184. PubMed ID: 30846243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal change in white matter microstructure in Huntington's disease: The IMAGE-HD study.
    Poudel GR; Stout JC; Domínguez D JF; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    Neurobiol Dis; 2015 Feb; 74():406-12. PubMed ID: 25497085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.
    Rosas HD; Salat DH; Lee SY; Zaleta AK; Pappu V; Fischl B; Greve D; Hevelone N; Hersch SM
    Brain; 2008 Apr; 131(Pt 4):1057-68. PubMed ID: 18337273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression.
    Novak MJ; Seunarine KK; Gibbard CR; Hobbs NZ; Scahill RI; Clark CA; Tabrizi SJ
    Cortex; 2014 Mar; 52():98-112. PubMed ID: 24405816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design optimization for clinical trials in early-stage manifest Huntington's disease.
    Frost C; Mulick A; Scahill RI; Owen G; Aylward E; Leavitt BR; Durr A; Roos RAC; Borowsky B; Stout JC; Reilmann R; Langbehn DR; Tabrizi SJ; Sampaio C;
    Mov Disord; 2017 Nov; 32(11):1610-1619. PubMed ID: 28906031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional changes during working memory in Huntington's disease: 30-month longitudinal data from the IMAGE-HD study.
    Poudel GR; Stout JC; Domínguez DJ; Gray MA; Salmon L; Churchyard A; Chua P; Borowsky B; Egan GF; Georgiou-Karistianis N
    Brain Struct Funct; 2015 Jan; 220(1):501-12. PubMed ID: 24240602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and connectivity changes during working memory in Huntington's disease: 18 month longitudinal data from the IMAGE-HD study.
    Georgiou-Karistianis N; Poudel GR; Domínguez D JF; Langmaid R; Gray MA; Churchyard A; Chua P; Borowsky B; Egan GF; Stout JC
    Brain Cogn; 2013 Oct; 83(1):80-91. PubMed ID: 23938592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing a longitudinal compensation model in premanifest Huntington's disease.
    Gregory S; Long JD; Klöppel S; Razi A; Scheller E; Minkova L; Johnson EB; Durr A; Roos RAC; Leavitt BR; Mills JA; Stout JC; Scahill RI; Tabrizi SJ; Rees G;
    Brain; 2018 Jul; 141(7):2156-2166. PubMed ID: 29788038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington's disease: 30 months IMAGE-HD data.
    Domínguez D JF; Poudel G; Stout JC; Gray M; Chua P; Borowsky B; Egan GF; Georgiou-Karistianis N
    Cortex; 2017 Jul; 92():139-149. PubMed ID: 28482181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortical dysfunction in patients with Huntington's disease during working memory performance.
    Wolf RC; Vasic N; Schönfeldt-Lecuona C; Ecker D; Landwehrmeyer GB
    Hum Brain Mapp; 2009 Jan; 30(1):327-39. PubMed ID: 18172852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of composite cognitive scores for tracking progression in Huntington's disease.
    Jones R; Stout JC; Labuschagne I; Say M; Justo D; Coleman A; Dumas EM; Hart E; Owen G; Durr A; Leavitt BR; Roos R; O'Regan A; Langbehn D; Tabrizi SJ; Frost C
    J Huntingtons Dis; 2014; 3(2):197-207. PubMed ID: 25062862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntington's Disease.
    Gregory S; Cole JH; Farmer RE; Rees EM; Roos RA; Sprengelmeyer R; Durr A; Landwehrmeyer B; Zhang H; Scahill RI; Tabrizi SJ; Frost C; Hobbs NZ
    J Huntingtons Dis; 2015; 4(4):333-46. PubMed ID: 26756590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease.
    Sritharan A; Egan GF; Johnston L; Horne M; Bradshaw JL; Bohanna I; Asadi H; Cunnington R; Churchyard AJ; Chua P; Farrow M; Georgiou-Karistianis N
    J Neurol Neurosurg Psychiatry; 2010 Mar; 81(3):257-62. PubMed ID: 19237387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline multimodal information predicts future motor impairment in premanifest Huntington's disease.
    Castro E; Polosecki P; Rish I; Pustina D; Warner JH; Wood A; Sampaio C; Cecchi GA
    Neuroimage Clin; 2018; 19():443-453. PubMed ID: 29984153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.